Abiolone acetate, a prostate cancer treatment drug, has entered the first imitation competition mode

Abytiga acetate was originally developed by BTG company in the UK, and Johnson & Johnson obtained the development license In April 2011, the US FDA approved the drug for prostate cancer treatment by priority review procedure; in September of the same year, the drug was authorized by the EU market Abiterone is a CYP17 inhibitor, which can be used in combination with prednisone in the treatment of patients with previously received chemotherapy containing paclitaxel to transfer castrated and refractory prostate cancer According to experts from FDA drug review and Research Center, abitrone can not only reduce the level of prostate specific antigen, but also help to narrow the tumor and prolong the life of patients with advanced prostate cancer Forecast data predicts that by 2015, the sales of abiolone will be US $600 million, accounting for 20% of the market share of similar drugs (hormone inhibitors); biomedtracker forecasts that the peak sales of abiolone will be US $2.6 billion (2021) At present, there are more than ten domestic enterprises that are trying to copy the drug, including Shijiazhuang Zhiheng pharmaceutical, Shanghai chuangnio pharmaceutical, Shandong innovative pharmaceutical, Hefei Xinfeng technology, Jiangsu aosaikang, Shenzhen Wanle, Guoyao Yixin pharmaceutical, Jiangxi Qingfeng pharmaceutical, etc Click to query the registration progress of abitrone acetate news extension: AstraZeneca and Johnson & Johnson have reached an agreement to jointly promote the prostate cancer drug abitrone pharmaceutical giant AstraZeneca and Johnson & Johnson in Japan, to jointly promote the use of zytiga, a subsidiary of Johnson & Johnson, for the treatment of the preceding adenocarcinoma AstraZeneca will promote the drug together with KK, a subsidiary of Johnson & Johnson, whose application for listing was submitted in July 2013 and is currently under review by the Ministry of health, labor and welfare of Japan The drug is expected to be approved soon as it has been approved by the US Food and Drug Administration (FDA) and the European Drug Administration (EMA) for the treatment of metastatic castration resistant prostate cancer Although the drug is marketed in Europe and the United States under the trade name of zytiga, neither company has specified the trade name for listing in Japan, but chose to refer to the name of its active ingredient, abiolone acetate Although the financing terms of the agreement were not disclosed, Marc dunoyer, who is responsible for AstraZeneca's global product and portfolio strategy, commented on the company's growing ambitions and cooperation in Japan "Japan is one of the fastest growing drug markets, where AstraZeneca has a good record of successfully developing and marketing innovative drugs," he said This agreement is a strong strategic match for AstraZeneca, which not only strengthens our focus on cancer as the core treatment area, but also strengthens the use of Japan as our main growth driver "AstraZeneca has also signed similar agreements in the past, such as the agreement with Amgen and the first three co pharmaceutical companies to promote Amgen's dinosemide (trade names xgeva and Prolia) in Japan for the treatment of bone tumor diseases AstraZeneca has plans to expand its presence in Japan, where it has stressed that Japan is a market with further potential for its mature brands, which can help offset its sales declines in Europe and the United States.